Core Insights - Propanc Biopharma has entered into a strategic financing agreement with Hexstone Capital for up to $100 million to accelerate its clinical pipeline development [1][4] - The initial conversion price for the preferred stock is set at $5.00 per share, representing a 280% premium over the recent closing price of $1.78 [1][3] - The financing aims to grow Propanc's treasury to a value of $100 million or more within the next twelve months, capitalizing on the evolving digital asset ecosystem [1][6] Transaction Overview - Propanc will issue 100 shares of Series C Convertible Preferred Stock with an initial investment of $1 million [2] - The preferred stock is convertible into common stock at an initial conversion price of $5.00 per share, with a beneficial ownership limitation of 4.99% [3] - Propanc will also issue 9,900 warrants to Hexstone, allowing the purchase of preferred stock at $9,999.99 each, totaling up to $99 million in potential funding [4] Company Background - Propanc Biopharma is focused on developing a novel therapeutic approach to prevent the recurrence and metastasis of solid tumors, particularly targeting pancreatic, ovarian, and colorectal cancers [6][7] - The company's lead product candidate aims to eradicate cancer stem cells by leveraging the anti-cancer potential of pancreatic proenzymes [6]